17th JBF Symposium
Advanced Search

Session Details

SymposiumSymposium : Biomarkers

[D2-A2]Shaping the Future of Biomarker Evaluation: Insights from Practice

Thu. Mar 5, 2026 10:25 AM - 11:55 AM JST
Thu. Mar 5, 2026 1:25 AM - 2:55 AM UTC
Medium Hall(2nd Floor)
Chairman:Tomohiro Nishimoto(Nippon Shinyaku Co., Ltd.), Tomoko Arakawa(Pfizer R&D Japan G.K.)
10:25 AM - 10:50 AM JST(1:25 AM - 1:50 AM UTC)

[D2-A2-01]Biomarker Calibrator Challenges for Assays supporting Clinical Drug Development

*Lindsay Ewan King1 (1. Pfizer Inc.)
Comment()
10:50 AM - 11:15 AM JST(1:50 AM - 2:15 AM UTC)

[D2-A2-02]Parallelism Best Practices for Biomarker Assay Validation and Application to LC-MS Approaches

*Barry R Jones1 (1. Crinetics Pharmaceuticals, Inc.)
Comment()
11:15 AM - 11:35 AM JST(2:15 AM - 2:35 AM UTC)

[D2-A2-03]Biomarker Evaluation in Human Tissue Samples: Practices and Perspectives

*Akiko Nagatsuma1, Ryoko Takubo1 (1. Chugai Pharmaceutical Co., Ltd.)
Comment()
11:35 AM - 11:55 AM JST(2:35 AM - 2:55 AM UTC)

[D2-A2-04]KRAS G12D IHC Assay Reveals Target Degradation by Setidegrasib in Cancer Patient Tumor Samples

*Toshiko Yahata1, Fumio Osaki1, Masayasu Yoshino1 (1. Astellas Pharma Inc.)
Comment()
Back to Category List